Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 507.20
Change Today 0.00 / 0.00%
Volume 0.0
RDHL On Other Exchanges
Tel Aviv
As of 10:24 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/15/15 - $910.10
52 Week Low
11/18/14 - $295.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company’s pipeline of therapeutic candidates include RHB-105, which is in Phase III clinical trial, intended for the eradication of Helicobacter pylori infection; and RHB-104 that is in Phase III clinical trial for the treatment of Crohn's disease, in Phase IIa proof of concept clinical trial for the treatment of multiple sclerosis, and under pre-clinical studies for the treatment of rheumatoid arthritis. Its pipeline of therapeutic candidates also comprise BEKINDA, which is under review with FDA, for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and in Phase III clinical trial for the treatment of gastroenteritis and gastritis; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. In addition, the company’s pipeline of therapeutic candidates consist of MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers, which has completed various Phase I clinical trials and two Phase II proof of concept clinical trials; RP101, a heat shock protein 27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers, which has completed various Phase I and Phase II clinical trials; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. Further, its pipeline of proprietary products comprises ABC294640, a Phase II-stage orally-administered sphingosine kinase-2 inhibitor targeting various inflammatory, gastrointestinal, and oncology indications. The company was founded in 2009 and is based in Tel Aviv, Israel.

10 Employees
Last Reported Date: 02/26/15
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $280.2K
Deputy Chief Executive Officer of Finance & O...
Total Annual Compensation: $237.6K
Senior Vice President of Research & Developme...
Total Annual Compensation: $233.2K
Senior Vice President of Corporate & Product ...
Total Annual Compensation: $216.0K
Chief Business Officer
Total Annual Compensation: $199.3K
Compensation as of Fiscal Year 2014.

redhill biopharma ltd (RDHL) Key Developments

RedHill Biopharma Announces Last Patient Visit in the Phase I Study with YELIVA(TM) (ABC294640) for Advanced Solid Tumors

RedHill Biopharma Ltd. announced that the last patient has completed the final scheduled follow-up visit in the Phase I study evaluating YELIVA™ (ABC294640), the company's orally-administered first-in-class sphingosine kinase-2 (SK2) selective inhibitor, for the treatment of advanced solid tumors (the ABC-101 study). The ABC-101 Phase I study was conducted at the Medical University of South Carolina Hollings Cancer Center and was led by Principal Investigators Melanie Thomas, MD, and Carolyn Britten, MD. The open-label, dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) first-in-human Phase I study of YELIVA™ (ABC294640) enrolled 22 patients with advanced solid tumors. The patients were continuously treated with the study drug in the absence of disease progression and evaluated for an additional period of up to one year after discontinuing treatment with YELIVA™ (ABC294640). The primary objectives of the study were to identify the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) and to evaluate the safety of YELIVA™ (ABC294640). The secondary objectives of the study were to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of YELIVA™ (ABC294640) and to assess its antitumor activity. The study was supported by grants from the National Cancer Institute (NCI) and the FDA'sOffice of Orphan Products Development (OOPD). Preliminary positive data from the Phase I study was presented by Apogee Biotechnology Corporation at the November 2013 Molecular Targets and Cancer Therapeutics meeting. The analysis of the study is currently ongoing and top-line results are expected to be announced early in the fourth quarter of 2015. A full analysis and the final Clinical Study Report (CSR) are expected by the end of the year or early 2016.

Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for Treatment of H. Pylori Infection

Recipharm AB announced that it has signed an agreement with RedHill Biopharma Ltd. for the manufacturing of RedHill's late-stage patented drug candidate, RHB-105. RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion. Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply. RHB-105 is a new and proprietary fixed-dose oral combination therapy of two antibiotics (amoxicillian and rifabutin) and a proton pump inhibitor (omeprazole) combined into an all-in-one oral capsule with a planned indication for treatment of H. pylori infection. In June of this year, RHB-105 successfully met its primary endpoint in its first Phase III study. This complex project straddles and integrates three of Recipharm's manufacturing facilities making it the first project of its kind within the organization. The FDA approved facilities in Fontaine and Pessac will manufacture the Omeprazole mini-tablets, whilst in Strangnäs the final product will be encapsulated and packaged ready for final release.

Redhill Biopharma Ltd. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

RedHill Biopharma Ltd. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s total revenues were $1,000 against $4,000 a year ago. Operating loss was $5,890,000 against $4,114,000 a year ago. Loss and comprehensive loss was $6,596,000 or $0.07 per basic and diluted share against $4,524,000 or $0.05 per basic and diluted share a year ago. Net cash used in operating activities was $4,680,000 against $4,164,000 a year ago. Purchase of fixed assets was $5,000 against $5,000 a year ago. Purchase of intangible assets was $1,500,000. For the six months, the company’s total revenues were $2,000 against $7,009,000 a year ago. Operating loss was $10,645,000 against $822,000 a year ago. Loss and comprehensive loss was $11,238,000 or $0.12 per basic and diluted share against $1,147,000 or $0.01 per basic and diluted share a year ago. Net cash used in operating activities was $8,052,000 against $2,488,000 a year ago. Purchase of fixed assets was $7,000 against $30,000 a year ago. Purchase of intangible assets was $1,575,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 507.20 0.00

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at